Dabrafenib Mesylate

Details:

English name DabrafenibMesylate
English synonyms DabrafenibMesylate(GSK-2118436); DabrafenibMesylate(GSK-2118436B); DabrafenibMesylate; GSK2118436Mesylate; GChemicalbookSK2118436B; GSK2118436Mesylate; GSK-2118436Mesylate; DabrafenibMesylate(API)CAS number 1195768-06-9
Molecular formula C24H24F3N5O5S3
Molecular weight 615.66
EINECS number 689-167-4

Customs Code: 2935909099

Melting point >234oC(dec.)
Storage conditions Hygroscopic, - 20 ° CFreezer, UnderinerChemicalbooktatmosphere
Solubility DMSO (slightly soluble, heated), methanol (slightly soluble) form of white solid.
Color White to white stability hygroscopicity

Dabrafenib is a drug developed by GlaxoSmithKline (GSK) in the United States to treat metastatic melanoma, a BRAF inhibitor cancer drug, in the form of mesylate for medicinal use, formerly known as GSK2118436, trade name Tafinlar. On May 29, 2013, the U.S. Food and Drug Administration (FDA) approved GlaxoSmithKline's Tafinlar (dabrafenib) and Mekinist (trametinib) for marketing. Tafinlar is approved for the treatment of unresectable melanomas (tumors that cannot be removed surgically) and metastatic melanomas (tumors that have spread to other organs in the body) carrying the BRAFV600E mutation, but not for the treatment of wild-type BRAF melanoma. Mekinist is indicated for the treatment of unresectable or metastatic melanomas carrying BRAFV600E or V600K mutations, and Mekinist should not be used in patients with melanoma who have previously used BRAF inhibitors.